Effective October 3, 2022, ethinyl estradiol and norethindrone contraceptive medications have been added to the ADAP formulary. Unintended pregnancy rates are high in the United States and are associated with increased morbidity for people with HIV. Prevention of unintended pregnancy is an important health need for cis women with HIV and other people with HIV who may become pregnant. Hormonal contraception with ethinyl estradiol and norethindrone is highly effective at preventing pregnancy and safe for use with HIV treatment medications. Adding ethinyl estradiol and norethindrone contraceptive medications to the ADAP formulary provides contraceptive options and helps to ensure that ADAP clients receive care consistent with current national guidelines.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary (https://cdph.magellanrx.com/member/documents) has been updated to reflect the addition of ethinyl estradiol and norethindrone contraceptive medications.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact James Vo, ADAP Specialist, at (916) 449-5965.
Sharisse Kemp, MSW
ADAP Branch Chief
California Department of Public Health